Drugging ATR: progress in the development of specific inhibitors for the treatment of cancer.
about
Non-thermal plasma-induced apoptosis is modulated by ATR- and PARP1-mediated DNA damage responses and circadian clock2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei.Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells.Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities.Targeting the ATR-CHK1 Axis in Cancer TherapyHsa-miR-520d-5p promotes survival in human dermal fibroblasts exposed to a lethal dose of UV irradiation.Novel Pieces for the Emerging Picture of Sulfoximines in Drug Discovery: Synthesis and Evaluation of Sulfoximine Analogues of Marketed Drugs and Advanced Clinical Candidates.Reevaluation of ATR signaling in primary resting chronic lymphocytic leukemia cells: evidence for pro-survival or pro-apoptotic function.A New, Practical One-Pot Synthesis of Unprotected Sulfonimidamides by Transfer of Electrophilic NH to Sulfinamides.Therapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumors.LC-MS/MS assay for the quantitation of the ATR kinase inhibitor VX-970 in human plasma.BRD4 facilitates replication stress-induced DNA damage response.Exploration of Novel Chemical Space: Synthesis and in vitro Evaluation of N-Functionalized Tertiary Sulfonimidamides.The ATR inhibitor AZD6738 synergizes with gemcitabine in vitro and in vivo to induce pancreatic ductal adenocarcinoma regression.
P2860
Q28821184-C830D4F3-84B7-4702-A6EE-791243D750FDQ33698756-D4023B3F-8DFB-465E-AB16-6BFD5D377F6FQ37635766-32FD5F0D-E81C-464C-97EB-49AB0D10C59FQ38739456-0838D95E-B00E-4B09-8BBA-84469A9C5A0CQ38805276-631AE8F8-26E8-4904-9519-4B4559DCDFA4Q38817102-B2E97FC9-32EA-4CE3-BDB5-59DC40E38571Q40117584-35903B31-F97B-4078-B4EE-21F262027CDFQ41039819-AF6F500F-A5AF-45A6-A043-90BA87244F9AQ41344084-D41BB356-7941-4555-86B8-52A1A8C37715Q45767567-2A67FC2B-00D9-4C58-97BF-203222FEB925Q46062200-E98B0E91-3C07-4B26-961A-125C3DBA172BQ47829412-5F77A25B-57C9-4D32-8202-C88A1C5EB699Q52595313-30E42CB6-B035-4C86-90A3-AA83C7229ECAQ52803327-CEC83C5C-3D34-4BE8-B25A-2484895D6BAAQ54976514-36A00E02-35B7-49F9-8B1F-28D40E5CAE29
P2860
Drugging ATR: progress in the development of specific inhibitors for the treatment of cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Drugging ATR: progress in the ...... s for the treatment of cancer.
@en
type
label
Drugging ATR: progress in the ...... s for the treatment of cancer.
@en
prefLabel
Drugging ATR: progress in the ...... s for the treatment of cancer.
@en
P2860
P356
P1476
Drugging ATR: progress in the ...... rs for the treatment of cancer
@en
P2093
Kevin M Foote
P2860
P304
P356
10.4155/FMC.15.33
P577
2015-01-01T00:00:00Z